Skip to main content
. 2016 Feb 4;8(4):305–311. doi: 10.4168/aair.2016.8.4.305

Table 3. Inter-visit difference in group B (placebo-montelukast group).

Phase I P value Phase II P value
Visit 2 (Week 0) Visit 4 (Week 8) Visit 5 (Week 10) Visit 7 (Week 18)
SCORAD index 34.7±13.7 30.5±12.5 0.31 28.0±14.1 25.9±11.9 0.60
U-LTE4 (pg/mL) 430.4±428.0 438.8±420.6 0.95 552.0±427.4 461.7±433.6 0.50
U-EDN (ng/mL) 755.2±787.7 584.8±722.7 0.47 671.3±657.1 981.3±788.1 0.17

SCORAD, SCORing Atopic Dermatitis; U-LTE4, Urine leukotriene E4; U-EDN, Urine eosinophil-derived neurotoxin.